Efficacy and Safety of Intravitreal Ranibizumab (Lucentis®) Injection in the Treatment of Non-leaking Macular Cysts in Patients With Retinal Dystrophy.
Phase of Trial: Phase II
Latest Information Update: 24 Sep 2019
Price : $35 *
At a glance
- Drugs Ranibizumab (Primary) ; Acetazolamide; Brinzolamide
- Indications Retinal dystrophies
- Focus Adverse reactions; Therapeutic Use
- 20 Sep 2019 Status changed from active, no longer recruiting to completed.
- 12 Dec 2018 New trial record